Edition:
United States

Paratek Pharmaceuticals Inc (PRTK.OQ)

PRTK.OQ on NASDAQ Stock Exchange Global Market

9.65USD
21 Sep 2018
Change (% chg)

$0.40 (+4.32%)
Prev Close
$9.25
Open
$9.20
Day's High
$9.68
Day's Low
$9.20
Volume
174,875
Avg. Vol
94,093
52-wk High
$26.00
52-wk Low
$9.05

Select another date:

Wed, Aug 8 2018

U.S. FDA panel backs approval of Paratek's antibiotic

A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

UPDATE 1-U.S. FDA panel backs approval of Paratek's antibiotic

Aug 8 A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

U.S. FDA panel backs approval of Paratek's antibiotic

Aug 8 A U.S. Food and Drug Administration expert panel on Wednesday voted in favor of approval of Paratek Pharmaceuticals Inc's antibiotic to treat bacterial pneumonia and skin infections.

Paratek antibiotic not inferior to current treatments: FDA staff

Paratek Pharmaceuticals Inc's new antibiotic for bacterial pneumonia and skin infections is not inferior to current treatments, U.S. Food and Drug Administration staff reviewers said on Monday.

UPDATE 1-Paratek antibiotic not inferior to current treatments-FDA staff

* Drug could bring in U.S. sales of $535 mln in 2025-analysts

BRIEF-Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91

* PARATEK PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Paratek Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* PARATEK ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

BRIEF-Highbridge Capital Management Reports 6.54 Pct Passive Stake In Paratek Pharmaceuticals

* HIGHBRIDGE CAPITAL MANAGEMENT, LLC REPORTS 6.54 PERCENT PASSIVE STAKE IN PARATEK PHARMACEUTICALS INC AS OF APRIL 23, 2018 - SEC FILING Source : https://bit.ly/2HIcM0E Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Paratek Pharmaceuticals Prices $140 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. PRICES $140 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

BRIEF-Paratek Pharmaceuticals Announces Proposed Private Offering Of $125 Mln Of Convertible Senior Subordinated Notes Due 2024

* PARATEK PHARMACEUTICALS, INC. ANNOUNCES PROPOSED PRIVATE OFFERING OF $125 MILLION OF CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2024

Select another date: